PFIZER/NEKTAR: EXUBERA TO ENJOY STRONG MID-TERM GROWTH

Pfizer's Exubera is expected to experience strong sales growth from 2007 to 2009. Pfizer and Nektar Therapeutics' Exubera looks set to experience strong mid-term growth in type 1 and type 2 diabetes, driven by patient interest and physician acceptance of efficacy and safety data. By 2010, global sales of the drug are expected to reach $2 billion. However, Wall Street expectations of strong first year sales may be disappointed due to pricing and reimbursement difficulties.
Pharmaceutical Business Review